Baxter (NYSE:BAX) today released data on its Sharesource remote patient monitoring and home-use Amia automated peritonial dialysis systems, touting its ability to improve early detection of adverse issue issues and faster treatment.
Data on the platforms was presented at the American Society of Nephrology’s annual Kidney Week meeting last week in Chicago.
Data from a case study of Baxter’s Sharesource indicated that the system was able to identify a displaced catheter through an early alert and diagnosis, which was surgically repositioned, the company said.
A simulation study of 12 APD patient profiles indicated that remote management of APD patients through telehealth can save approximately $22,000 in healthcare resources associated with treatment non-adherence, fluid overload and missing data.
The company also presented data on its Amia APD system indicating that a clinic using the system was able to provide more efficient training for patients, who returned home on average a day sooner than they would on legacy APD systems.
”Data on the use of Baxter’s AMIA APD system and the Sharesource telehealth platform tell us the technology is enhancing dialysis clinic efficiencies. For the first time, physicians have more reliable visibility to their patient’s home therapy, which helps them identify potential clinical and therapy adherence issues sooner so that informed decisions can be addressed more quickly,” medical affiards veep Dr. Dheerendra Kommala said in a press release.
In June, Baxter said it won Canadian approval for its Amia automated peritoneal dialysis system.
The Health Canada approval makes Amia the 1st automated peritoneal dialysis device cleared in the U.S. and Canada that includes voice guidance, touchscreen control and 2-way telemedicine features, Baxter said.
Earlier in June, Baxter CEO Jose Almeida said the company is getting out of the home hemodialysis business, ceding the field to market leader NxStage Medical (NSDQ:NXTM).